Heidelberg Pharma AG banner

Intrinsic Value

The intrinsic value of Heidelberg Pharma AG (HPHA) under the Base Case is 2.63 EUR per share. Compared with the current market price of 2.08 EUR, the stock appears Undervalued by 21% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

HPHA Intrinsic Value
€2.63
Undervaluation 21%
Intrinsic Value
Price €2.08

HPHA is cheaper than usual. This is its cheapest valuation in the past 5 years.

Alert me when HPHA is below its intrinsic value
Today €1.84 · 11.5% below the current price
Alternatives to HPHA

Fundamental Analysis

What Heidelberg Pharma Does

Biotechnology Health Care

Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin.

Headquarters
Germany DE
Employees
60
IPO date
Nov 13, 2006
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue HPHA Research

Decided on Heidelberg Pharma? Get an email when HPHA reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one HPHA stock?

The intrinsic value for Heidelberg Pharma AG (HPHA) under the Base Case is 2.63 EUR.

Is HPHA stock undervalued or overvalued?

Compared with the current market price of 2.08 EUR, the stock appears Undervalued by 21% .

How reliable are our estimates? See how past valuations played out
Back to Top